AXSM trade ideas
AXMS - UP UP! The trend is your friend!EN: This sotck also woke up Friday, he could go reach my target. His lower trend line is very reliable.
FR: Ce sotck aussi s'est réveillé vendredi, il pourrait aller atteindre ma cible. Sa ligne de tendance inférieure est très fiable.
AXSM - Uptrend! Next target - $35EN : Last Friday, certainly announces a reversal and possibly a return to the top to reach the $ 35. At least four times, the stock has stumbled on its bottom line of mid-term trend andd Friday, it was probably the 5th time.
FR: La journée de vendredi dernier annonce assurément un renversement et possiblement un retour vers le haut pour atteindre le 35$. Au moins à 4 reprises, le titre s'est buté sur sa ligne inférieure de sa tendance moyen terme et vendredi, ce fut surement la 5ème fois.
Expecting a classical ABC correctionI think its reasonable to assume an ABC correction here given that wave 2 was a relatively short and small correction. Such correction would put us through the path of completing the fifth wave
$AXSMSeems that 13.91 is acting as a tough support level. If that is broken, we have a pretty big fade coming.
AXSM Going Parabolic!I first started tracking AXSM on Monday Jan 7th (Pre-market at approx. $5.00), and it has since Sky-Rocketed to a high of $17.05 today pre-market Tuesday March 26th representing 248% in Gains, locking in enormous profits.
significantly improved symptoms of depressionsignificantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD)
finance.yahoo.com
Massive short squeeze in Overcrowded stockWhen the short is so obvious and everybody is doing it - You have to go long.
All short will blow their accounts if not taking proper size.
AXSM Stock Review!Hello everyone! Today I have a short term chart analysis for AXSM. You can see the FULL video analysis by clicking the link below in my signature description!
I have new updated charts, and new video's every day. Please follow me on tradingview, and subscribe to me on youtube!
Leave any questions or comments below, and I will get back to you as soon as possible!
200% gain on positive data?Positive data for one drug trial is not nearly enought to justify such a drastic increase in price.
Risk takers: AXSM: Again looks promising to me. Warning: High risk pharmaceutical company. I was early in my last chart in January.
Chart looks more promising to me now. The company is developing non opioid treatments for joint pain, depression, and Alzheimer's disease. Pipeline (see ling below) is in clinical trials. If trials fail often get large drops in price and vice versa. With the opioid crisis IF these meds are helpful would be great potential. Watch for breakup above "1". Have a great weekend.
axsome.com
recent news: seekingalpha.com
AXSM: biotech stock: one to watch Possible double bottom. Watch if holds here.
See “the gold bags” post:
News today:
finance.yahoo.com
AXSM could be the next 4 - 6 bagger biotechstockCash: $41 Million (cash runway into the second quarter of 2019)
Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)
•Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)
•Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)
7 x Phase 3 Programs in Pipeline :
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions in Phase 3 (SPA & Fast Track) ---7M patients in the U.S.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) ---No approved drug = high unmet need. 80,000 new cases per year in the U.S.
AXS-02 Chronic Low Back Pain Associated with Modic Changes in Phase 3 ---1.6M patients in the U.S.
AXS-05 Agitation in patients with Alzheimer’s disease(AD) in Phase 2/3 ---No approved medication = unmet medical need. 2M patients in the U.S.
AXS-05 STRIDE-1 Treatment resistant depression in Phase 3 ---Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.
AXS-06(MoSEIC™ Mx + Eso) Acute and Chronic Pain Phase 3 Ready = 120M NSAID TRx per year in the U.S.
AXS-07 (meloxicam and rizatriptan) for the Treatment of Migraine Phase 3 Ready = Migraine attacks are disabling and affect more than 37 million Americans
Second Axsome AXSM buy opportunityCurrent share price is testing the upward trending lower resistance line. As the lower resistance line crosses the $5 inflection line we could expect major movement ahead of the Q42017/Q12018 FDA catalysts.
